Early trial findings suggest that copper depletion may promote tumor dormancy in patients at high risk for recurrent breast cancer. The phase II study indicates that treatment with the anti-angiogenic copper chelator tetrathiomolybdate (TM) reduced the number of bone marrow-derived endothelial progenitor cells (EPCs) in women with triple-negative breast cancer, and thus halted recurrence. Read more here.
Study mentioned: Jain S, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol. 2013 Feb 13. [Epub ahead of print] PMID: 23406736
No comments:
Post a Comment